Acrivon Therapeutics Common StockNASDAQ: ACRV

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 November 2022

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$198.65 M
-60%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-67%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 21:00:02 GMT
$6.38+$0.18(+2.90%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ACRV Latest News

Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
zacks.com21 June 2024 Sentiment: POSITIVE

Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
seekingalpha.com13 June 2024 Sentiment: POSITIVE

Acrivon Therapeutics, Inc. is an oncology-focused biotech using a multi-targeted panel to identify patients for clinical trials. Acrivon Therapeutics is focused on ACR-368, a CHK1/2 inhibitor, with promising results in gynecologic cancers using their OncoSignature platform. Financially stable with $112.1 million in assets, Acrivon Therapeutics CRV has the potential for accelerated approval and future pipeline expansion.

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
zacks.com28 May 2024 Sentiment: POSITIVE

Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.

5 Small Drug Stocks to Buy From a Recovering Industry
zacks.com24 May 2024 Sentiment: POSITIVE

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
zacks.com20 May 2024 Sentiment: POSITIVE

Here is how Acrivon Therapeutics, Inc. (ACRV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data
Market Watch24 April 2024 Sentiment: POSITIVE

Acrivon Therapeutics saw a rise in shares during after-hours trading following the announcement that they will be sharing clinical trial results related to a biomarker test for ovarian and endometrial cancers.

ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
InvestorPlace09 April 2024 Sentiment: POSITIVE

Acrivon Therapeutics (NASDAQ: ACRV) stock is surging today following the announcement of a $130 million private placement from a mix of existing and new accredited investors through a PIPE transaction.

What To Buy After You Sell The Russell 2000
Seeking Alpha03 April 2024 Sentiment: NEUTRAL

What To Buy After You Sell The Russell 2000

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
GlobeNewsWire05 March 2024 Sentiment: POSITIVE

ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies

7 Up-and-Coming Stocks to Buy for the Next Decade
InvestorPlace29 June 2023 Sentiment: POSITIVE

In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the heat in terms of overall sexiness, some folks just can't handle adventurous portfolios.

What type of business is Acrivon Therapeutics Common Stock?

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

What sector is Acrivon Therapeutics Common Stock in?

Acrivon Therapeutics Common Stock is in the Healthcare sector

What industry is Acrivon Therapeutics Common Stock in?

Acrivon Therapeutics Common Stock is in the Biotechnology industry

What country is Acrivon Therapeutics Common Stock from?

Acrivon Therapeutics Common Stock is headquartered in United States

When did Acrivon Therapeutics Common Stock go public?

Acrivon Therapeutics Common Stock initial public offering (IPO) was on 15 November 2022

What is Acrivon Therapeutics Common Stock website?

https://www.acrivon.com

Is Acrivon Therapeutics Common Stock in the S&P 500?

No, Acrivon Therapeutics Common Stock is not included in the S&P 500 index

Is Acrivon Therapeutics Common Stock in the NASDAQ 100?

No, Acrivon Therapeutics Common Stock is not included in the NASDAQ 100 index

Is Acrivon Therapeutics Common Stock in the Dow Jones?

No, Acrivon Therapeutics Common Stock is not included in the Dow Jones index

When was Acrivon Therapeutics Common Stock the previous earnings report?

No data

When does Acrivon Therapeutics Common Stock earnings report?

The next expected earnings date for Acrivon Therapeutics Common Stock is 28 March 2025